Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as PF-06954522 MR (Formulation 2)
PF-06954522 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Part A | EXPERIMENTAL | Multiple doses of PF 06954522 or placebo daily for up to 8 weeks in adult participants with T2DM in up to 7 cohorts. |
| Part B (Optional) | EXPERIMENTAL | Multiple doses of PF 06954522 or placebo daily for up to 8 weeks in non-diabetic adult participants with obesity in up to 3 cohorts. |
| Part C (Optional) | EXPERIMENTAL | An 8-period multiple-dose assessment of the effect of PF-06954522 on rosuvastatin, midazolam, and omeprazole PK in healthy adult participants for up to 14 weeks in healthy adult participants. |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Oral tablet |
| Rosuvastatin | DRUG | Oral tablet |
| Midazolam | DRUG | Oral suspension |
| Omeprazole | DRUG | Oral tablet |
| PF-06954522 | DRUG | Oral tablet |
Inclusion Criteria: * Female participants of non-childbearing potential and males between the ages of 18 and 70 years, inclusive, at the time of signing the ICD. * Part A only: Diagnosis of Diabetes - Participants enrolling with T2DM must have a clinical history of T2DM and be taking metformin mono...
PF-06954522 is an investigational small molecule developed by Pfizer, Inc. for Type 2 Diabetes Mellitus. It is in Phase 1 clinical development and has been studied in a single completed trial of 50 participants. It is not approved for any use.
PF-06954522 is being studied for the treatment of Type 2 Diabetes Mellitus, with a completed Phase 1 trial that also enrolled participants with obesity. It is an investigational agent and has not been approved for prescribing in T2DM or any other condition.
Pfizer, Inc. (ticker PFE) is the developer of PF-06954522. The company sponsored the Phase 1 study of the compound in adults with Type 2 Diabetes Mellitus conducted in the United States.
PF-06954522 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. The compound remains investigational and has not received regulatory approval for Type 2 Diabetes Mellitus or any other indication.
PF-06954522 has been evaluated in one completed Phase 1 trial, NCT06279234, titled a study to learn how different amounts of PF-06954522 are tolerated and act in adults with Type 2 Diabetes Mellitus. The trial enrolled 50 participants in the United States and included a controlled, randomized design.
Yes. PF-06954522 MR (Formulation 2) is an alternative name for PF-06954522, the Pfizer small molecule studied in Type 2 Diabetes Mellitus. Searches using either name refer to the same investigational compound.